Treatment with selinesol tablets may extend patients' lives by several years

Selinexor (Selinexor) is the first oral selective inhibitor of nuclear export (SINE) compound. Selinisol works by binding to and inhibiting the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the nucleus. This reactivates and amplifies their tumor suppressor function and is thought to lead to the selective induction of apoptosis in cancer cells while largely sparing normal cells.

Selinisol was first approved by the U.S. Food and Drug Administration (FDA) in combination with dexamethasone in patients with heavily pretreated myeloma. This is based on the STORM (Selinesol in Relapsed Myeloma) trial. In this study, a total of 122 patients were included in the modified intention-to-treat population (preliminary analysis) and 123 were included in the safety population. The median age was 65 years and the median number of previous treatment regimens was 7; a total of 53% of patients had high-risk cytogenetic abnormalities. Partial responses or better were observed in 26% of patients, including two stringent complete responses. The clinical benefit rate (minimal CBR response or better) was 39%. The median duration of response was 4.4 months, the median progression-free survival (PFS) was 3.7 months, and the median overall survival was 8.6 months. For patients who achieved molecular response (MR) or better, median overall survival was 15.6 months.

Generally speaking, the goals of treatment with medications are to control or slow the progression of cancer and improve the patient's quality of life. However, extending life is a complex issue because it involves many factors, including the patient's overall health, age, comorbidities, treatment options, healthcare environment, and more. So whether using selinesol tablets can extend a patient's life depends on the patient's specific situation and type of disease.